In Vivo Pharmacology Models for Cancer Target Research
Author:
Publisher
Springer New York
Link
http://link.springer.com/content/pdf/10.1007/978-1-4939-9145-7_12
Reference39 articles.
1. Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, Li Y, Fine EJ, Wu X, Shalem O, Cradick TJ, Marraffini LA, Bao G, Zhang F (2013) DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 31(9):827–832. https://doi.org/10.1038/nbt.2647
2. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F (2013) Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8(11):2281–2308. https://doi.org/10.1038/nprot.2013.143
3. Stovall DB, Wan M, Zhang Q, Dubey P, Sui G (2012) DNA vector-based RNA interference to study gene function in cancer. J Vis Exp 64:e4129. https://doi.org/10.3791/4129
4. Li QX, Feuer G, Ouyang X, An X (2017) Experimental animal modeling for immuno-oncology. Pharmacol Ther 173:34–46. https://doi.org/10.1016/j.pharmthera.2017.02.002
5. Ke N, Zhou D, Chatterton JE, Liu G, Chionis J, Zhang J, Tsugawa L, Lynn R, Yu D, Meyhack B, Wong-Staal F, Li QX (2006) A new inducible RNAi xenograft model for assessing the staged tumor response to mTOR silencing. Exp Cell Res 312(15):2726–2734. https://doi.org/10.1016/j.yexcr.2006.05.001
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models;Scientific Reports;2024-04-19
2. Mathematical modeling of tumor based on in vitro and in vivo data, and in vitro to in vivo extrapolation and its challenges: a literature review;2023 IEEE 23rd International Symposium on Computational Intelligence and Informatics (CINTI);2023-11-20
3. HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models;Scientific Reports;2023-04-03
4. Truncated FGFR2 is a clinically actionable oncogene in multiple cancers;Nature;2022-08-10
5. Translational and Clinical Relevance of PDX‐Derived Organoid Models in Oncology Drug Discovery and Development;Current Protocols;2022-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3